55 related articles for article (PubMed ID: 25942361)
1. Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.
Singh PK; Fan H; Jiang X; Shi L; Nathan CF; Lin G
ChemMedChem; 2016 Oct; 11(19):2127-2131. PubMed ID: 27561172
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents.
Almaliti J; Miller B; Pietraszkiewicz H; Glukhov E; Naman CB; Kline T; Hanson J; Li X; Zhou S; Valeriote FA; Gerwick WH
Eur J Med Chem; 2019 Jan; 161():416-432. PubMed ID: 30384045
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
Kumar S; Malachowski WP; DuHadaway JB; LaLonde JM; Carroll PJ; Jaller D; Metz R; Prendergast GC; Muller AJ
J Med Chem; 2008 Mar; 51(6):1706-18. PubMed ID: 18318466
[TBL] [Abstract][Full Text] [Related]
4. Substituted quinolines as noncovalent proteasome inhibitors.
McDaniel TJ; Lansdell TA; Dissanayake AA; Azevedo LM; Claes J; Odom AL; Tepe JJ
Bioorg Med Chem; 2016 Jun; 24(11):2441-2450. PubMed ID: 27112450
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
[TBL] [Abstract][Full Text] [Related]
6. Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S
Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960
[TBL] [Abstract][Full Text] [Related]
7. A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.
Trader DJ; Simanski S; Kodadek T
J Am Chem Soc; 2015 May; 137(19):6312-9. PubMed ID: 25914958
[TBL] [Abstract][Full Text] [Related]
8. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK
Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913
[TBL] [Abstract][Full Text] [Related]
9. Macrocyclic Peptides that Selectively Inhibit the
Zhang H; Hsu HC; Kahne SC; Hara R; Zhan W; Jiang X; Burns-Huang K; Ouellette T; Imaeda T; Okamoto R; Kawasaki M; Michino M; Wong TT; Toita A; Yukawa T; Moraca F; Vendome J; Saha P; Sato K; Aso K; Ginn J; Meinke PT; Foley M; Nathan CF; Darwin KH; Li H; Lin G
J Med Chem; 2021 May; 64(9):6262-6272. PubMed ID: 33949190
[TBL] [Abstract][Full Text] [Related]
10. Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties.
Angulo-Elizari E; Henriquez-Figuereo A; Morán-Serradilla C; Plano D; Sanmartín C
Eur J Med Chem; 2024 Mar; 268():116249. PubMed ID: 38458106
[TBL] [Abstract][Full Text] [Related]
11. Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp.
Chlipala GE; Sturdy M; Krunic A; Lantvit DD; Shen Q; Porter K; Swanson SM; Orjala J
J Nat Prod; 2010 Sep; 73(9):1529-37. PubMed ID: 20825206
[TBL] [Abstract][Full Text] [Related]
12. Psoralen Derivatives as Inhibitors of
Rožman K; Alexander EM; Ogorevc E; Bozovičar K; Sosič I; Aldrich CC; Gobec S
Molecules; 2020 Mar; 25(6):. PubMed ID: 32178473
[TBL] [Abstract][Full Text] [Related]
13. The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium.
Pereira AR; Kale AJ; Fenley AT; Byrum T; Debonsi HM; Gilson MK; Valeriote FA; Moore BS; Gerwick WH
Chembiochem; 2012 Apr; 13(6):810-7. PubMed ID: 22383253
[TBL] [Abstract][Full Text] [Related]
14. Napyradiomycins CNQ525.510B and A80915C target the Hsp90 paralogue Grp94.
Farnaes L; La Clair JJ; Fenical W
Org Biomol Chem; 2014 Jan; 12(3):418-23. PubMed ID: 24292715
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors.
Pacifico S; Ferretti V; Albanese V; Fantinati A; Gallerani E; Nicoli F; Gavioli R; Zamberlan F; Preti D; Marastoni M
ACS Med Chem Lett; 2019 Jul; 10(7):1086-1092. PubMed ID: 31312413
[TBL] [Abstract][Full Text] [Related]
16. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
17. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
Guedes RA; Serra P; Salvador JA; Guedes RC
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
[TBL] [Abstract][Full Text] [Related]
18. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
